OGT to discuss the latest tools for cytogeneticists at AMP and ASHG
Oxford Gene Technology (OGT), provider of innovative genetics research and biomarker solutions to advance molecular medicine, will be hosting booths at two key US cytogenetics meetings over the next few weeks. The first is the Association for Molecular Pathology (AMP) Annual Meeting on Genomic Medicine 2012 to be held in Long Beach, CA (25-27 October), and the second the American Society of Human Genetics Annual Meeting 2012 in San Francisco, CA (6-10 November). Researchers can visit the OGT booths to discuss the challenges currently facing molecular pathology research with the company’s experts. Perhaps most excitingly, OGT will be making a major announcement at the ASHG meeting, full details of which will be made publicly available after the meeting.
OGT has significant expertise in the area of cytogenetic analysis and has recently released a new series of microarrays specifically enhanced for investigating the genetic basis of cancer and other congenital diseases, including the CytoSure™ Haematological Cancer +SNP Array and the CytoSure ISCA +SNP Array, with enhanced SNP resolution. By combining both aCGH and SNP probes, these arrays make it is possible to carry out the accurate and cost-effective detection of both copy number changes and loss of heterozygosity, all in a single experiment. Analysis is further optimised via seamless integration with OGT’s powerful CytoSure Interpret Software, which rapidly and intuitively guides researchers to the important genetic variations in their samples, without the need for extensive bioinformatics expertise.
For further information, please contact:
Oxford Gene Technology, Begbroke Science Park, Begbroke Hill, Woodstock Road, Begbroke, Oxfordshire, OX5 1PF, U.K.
Special Note for Editors:
Meet OGT’s CEO, Dr Mike Evans, at ASHG 2012
To coincide with a major OGT announcement at ASHG, Dr Mike Evans will be available for interview by the media. This is a great opportunity to get exclusive, rapid insight into OGT’s ongoing strategy for best serving the needs of genomics research.
Meeting slots will be available on a first come, first serve basis — book yours now by emailing email@example.com or calling +44 (0) 1865 856828.
Notes for editors:
About Oxford Gene Technology
Founded by Professor Ed Southern, Oxford Gene Technology (OGT) provides innovative genetics research and biomarker solutions to advance molecular medicine. The company has two trading businesses: Genomics comprises of CytoSure™ cytogenetics array, labelling and interpretation software products and services for the detection of chromosomal abnormalities, and Genefficiency™ Genomic Services, a unique combination of platforms, expertise and processing capabilities to deliver rapid, relevant genomic data. The Biomarkers business utilises proprietary next generation technologies to build a rich patent-protected portfolio of promising biomarkers for early stage cancer detection including advanced programmes in colorectal and prostate cancer plus the autoimmune disease systemic lupus erythematosus.
CytoSure™ and Genefficiency™ NGS browser: For Research Use Only; Not for Use in Diagnostic Procedures
CytoSure: This product is provided under an agreement between Agilent Technologies, Inc., and OGT. The manufacture, use, sale or import of this product may be subject to one or more of U.S. patents, pending applications, and corresponding international equivalents, owned by Agilent Technologies, Inc. The purchaser has the non-transferable right to use and consume the product for RESEARCH USE ONLY AND NOT for DIAGNOSTICS PROCEDURES. It is not intended for use, and should not be used, for the diagnosis, prevention, monitoring, treatment or alleviation of any disease or condition, or for the investigation of any physiological process, in any identifiable human, or for any other medical purpose.